Masaru Taniguchi’s group focuses on understanding the development and function of NKT cells by using various technologies, including ES or iPS cells, and also on clinical trials of NKT cell-targeted therapy for the patients with lung cancer and head and neck tumor in collaboration with Chiba University Hospital and National Hospital Organization. His group has also interested in the development of synthetic glycolipids for specific activation of NKT cells as agents to promote clinical applications for treatment or prevention of IgE-mediated allergy, autoimmune diseases and cancer. He is currently Senior Advisor and Group Director, Laboratory for Immune Regulation at RIKEN Center for Integrative Medical Sciences (Yokohama Japan).